Navigation Links
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting

nd demonstrated that the electroporation-enhanced immune responses to a hepatitis C DNA vaccine were capable of eliminating all liver cells that produced a model hepatitis C virus gene, simulating a potential cure of hepatitis C infection. Vaccination by methods not employing Inovio's technology were less or not effective.

Two other Inovio presentations reported electroporation device innovations including the Elgen 1000 system and a single-needle device. The Elgen 1000 system, which recently received CE marking, consists of an advanced pulse generator and a two-needle DNA injector that delivers the genes and electroporation pulses in a single step. The pulse generator allows flexible programming of pulse and injection parameters via a flash card operated personal computer, as well as comprehensive recording and storage of electroporation and patient data. The single needle device, in early development, allows injection of the DNA and electroporation with a single needle resembling a normal injection needle and applies pulses of lower voltage than those delivered by presently used devices, thus reducing the electrical sensation experienced by the patient.

"We are pleased with the performance of our DNA delivery technology in advanced preclinical studies. Together with our continuing innovations in electroporation devices, our technology may be able to make critical contributions to the development of novel, effective vaccines for the treatment or prevention of major life-threatening infectious diseases," said Dr. Avtar Dhillon, Inovio's president and CEO.

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:8/4/2015)... 2015 BioElectronics Corporation (OTC Pink: BIEL), ... Therapy medical devices, announced today that its registry ... trial device has been published in the prominent ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain ... assessment.  Chronic pain is a ...
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... 4, 2015  Ironshore Pharmaceuticals & Development, Inc. ... a company specializing in personalized medicine, to participate ... designed to evaluate the safety and efficacy of ... Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s second clinical ... originally partnered with Ironshore in 2014 and continues ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:8/4/2015)... ... August 05, 2015 , ... The Journal of Pain Research has ... corresponding author Professor Akiko Okifuji says “Both obesity and chronic pain are serious public ... say that one causes the other. Rather, there appear to be multiple factors that ...
(Date:8/4/2015)... ... August 04, 2015 , ... Atlantic Health System, one of the largest ... Fortune among the top five in their list of the 20 Best Workplaces in ... and Chilton Medical Centers, Goryeb Children’s Hospital and Atlantic Rehabilitation, is the highest-ranking company ...
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July 27th by ... viable method for encouraging people to lose weight. Specifically the study compared control patients ... loss success, adding a financial incentive to the overall incentive of increased health. According ...
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, Inc. ... Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, 2015. ... Dr. Carmona said. "I strongly believe in the mission of the company and ...
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts in chronic ... The Pain Antidote , which provides strategies for people who suffer from chronic ... Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an author who ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... uncovered a vital new biological clue that could lead ... that currently kills more than 60 per cent of ... Brain Tumour Research Centre, working on behalf of the ... role of the WNT biological pathway in central nervous ...
... Cite Compliance with Regulatory Bodies as Top Driver ... to a Sparta Systems sponsored survey unveiled at ... quality-related headlines have had little impact on managers, ... efforts. Instead, the majority of respondents - ...
... Millions of Dollars in Paper, Printing and Mailing Costs ... Corporation (NYSE: EMC ), the world leader ... Cross (IBC), a leading health insurer, has been named ... an independent research and consulting firm focused on the ...
... pharmaceutical and bio-sciences owner operators helps greatly ... facility in a validated stateHUNTSVILLE, Ala., March ... engineering software provider, introduced today SmartPlant(R) for ... the cost of construction and qualification/commissioning activities ...
... CareBETHESDA, Md., March 18 The Cystic Fibrosis Foundation ... leadership in improving the quality of care for people ... Quality Assurance (NCQA).The outlook for people with CF continues ... by the Foundation. In the 1950s, few children with ...
... a Long-Acting Interferon and Ribavirin Will Earn Decision ... in 2012, According to a New Report from ... one of the world,s leading research and advisory ... surveyed gastroenterologists and hepatologists identify a therapy,s effect ...
Cached Medicine News:Health News:Study finds biological clue in brain tumor development 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 3Health News:EMC Document Sciences(R) xPression(R) Helps Independence Blue Cross Win Recognition as 2009 Celent Model Carrier 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 3Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 4Health News:Cystic Fibrosis Foundation to Receive Prestigious Health Care Award 2Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 2Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 3
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
ISI Ultra-Light Specialty Table offers the ultimate accessibility for surgeons, technicians and equipment during upper extremity surgeries....
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
Medicine Products: